MGC Pharmaceuticals Limited
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Roby Reuven Zomer
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1202 Hay Street West Perth WA Australia 6005
- IPO Date
- Feb 22, 2017
- Website
- mgcpharma.com.au
- Similar Companies
- Business
- MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
Company News
Argent BioPharma hails US listing; appoints new CFO
MGC Pharma reports progress 'across all fronts'
MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation
MGC Pharmaceuticals unveils fundraise as global push planned
MGC Pharmaceuticals granted Saudi FDA approval for ArtemiC™
MGC Pharma receives Saudi approval for ArtemiC
MGC Pharmaceuticals clarifies share consolidation and new fundraise
MGC Pharmaceuticals proposes financial and capital restructuring plan
MGC Pharmaceuticals hails pivot to medical products, legacy sales hit
MGC Pharmaceuticals proposes fundraising for Australian investors
MGC Pharma hails good quarter as UK patients get CannEpil
Small-cap movers: MGC Pharma, Versarien and the end of cheap money
MGC Pharmaceuticals raises £0.7mln for working capital
MGC Pharmaceuticals clarifies shape of recent AMC Pharma order
MGC Pharma bags $1 million US order
MGC Pharma dismisses executive for share trading breaches
Wall Street set for higher open as debt deal is sealed ahead of May jobs report
CBI to axe staff as it fights for survival
MGC Pharmaceuticals delivers first CannEpil doses to UK patients; opens doors for refractory epilepsy treatment
MGC Pharmaceuticals announces boardroom changes, reflecting its shift of focus